ADC Plasma Stability Assay
The expert scientists at iQ Biosciences perform Plasma Stability Assays to assess the stability of antibody-drug conjugates (ADCs)—an essential factor in optimizing drug delivery while minimizing off-target toxicity—using high-quality plasma from mouse, rat, cynomolgus monkey, and human sources. We evaluate drug-antibody ratio (DAR) loss over time and small molecule payload release to help predict therapeutic efficacy and safety before advancing to preclinical models. Our LC-MS-based approach provides precise, high-resolution data, enabling better-informed decisions on ADC stability, potency, and pharmacokinetics in vivo.
Our services
- Evaluate the stability of your ADC candidate in high-quality plasma or serum from multiple species, including mouse, rat, cynomolgus monkey, and human.
- Assess drug-antibody ratio (DAR) loss over time with precise LC-MS analysis.
- Conduct all assays with high-quality reagents and strict controls (e.g., buffer-matched time points).
- Deliver data in user-friendly formats such as PowerPoint, Excel, or GraphPad Prism for easy interpretation.
The iQ Experience
Tailored Experiments
Your research is important to us. Our scientists will work through each step of the process with you, including assay design, data analysis, and recommendations for future studies.
Streamlined Process
Simplify your workflow. Bypass the middle-man: at iQ Biosciences, you’ll get immediate access to our biospecimen inventory, saving you both valuable time and money.
Expertise
We’re experts – so you don’t have to be. Augmenting years of experience in immunology and working with immune assays, our scientists stay current with the latest publications and technology.
Exceptional Service
We’re here to help. We know the challenges you’re facing: whether it be through expedited service or our complimentary consulting services, our team is dedicated to helping you reach your goals.
Service overview
How can iQ Biosciences help achieve your goals the smarter way?
ADC stability in circulation is critical for maximizing drug delivery to target while minimizing off-target toxicity. At iQ Biosciences, we offer plasma stability assays in mouse, rat, cynomolgus monkey, and human plasma or serum samples to help you predict therapeutic efficacy and assess safety risk before investing time and effort into preclinical animal models.
In our plasma stability assays, ADCs are incubated with high-quality plasma from species of interest and sample aliquots are taken over a range of time points, often across seven days, and stored until analysis. The target antibody of interest (ADC) is then isolated from the samples by immunoaffinity capture for intact ADC LC-MS analysis. Additionally, after ADC elution, the plasma supernatant can be used to quantify small molecule payload release. Utilizing these data, you can better predict important drug characteristics in vivo, including safety, potency, and pharmacokinetics.
(A) Plasma stability assay of Trastuzumab-vc-MMAE ADC (‘Tras-MMAE’). MMAE was conjugated to Trastuzumab monoclonal antibody at an average drug-antibody ratio (DAR) of 3.8. Tras-MMAE was incubated in either C57BL/6 mouse plasma or buffer control for 7 days, with samples collected on Days 0, 1, 2, 3, 5, and 7. The ADC was isolated from the samples by immunoaffinity capture and the DAR analyzed over the time course by LC-MS. Minimal DAR loss was observed in the buffer control samples (black) compared to the mouse plasma samples (red).
Order Information
Pricing
At iQ Biosciences, we understand that each client is unique. Upon quote request, we will provide complimentary consulting services to determine how to tailor our services to best meet your goals. Based on this preliminary assessment, we will be able to provide a price quote.
Expected Timetable
Fit a timetable appropriate to your research goals. We work with you to determine your expected turn-around on a case-by-case basis and ensure that our services fit your needs. Some experiments may require an expedited service – please inquire for more information.
